Given the apparent cardiovascular benefit of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in patients with type 2 diabetes (T2D), studies have been conducted to explore the potential mediation mechanisms underlying the additional treatment effect beyond glycemic control, with several clinical biomarkers, including glycated hemoglobin (HbA1c), urine albumin-to-creatinine ratio (UACR), and systolic blood pressure (SBP), identified as significant mediators [1, 2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.